Podcasts |

A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

In season 4, episode 12 of Targeted Talks, Federico Albrecht, MD, gives and account of 2 cases of patients with small cell lung cancer and how these patients were treated.

In season 4, episode 11 of Targeted Talks, Krisda Chaiyachati, MD, MPH, MSHP, discusses the social determinants of health for patients with cancer and key challenges for patients, like transportation insecurity.

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

In season 4, episode 8 of Targeted Talks, Ruchi Garg, MD, discusses treatment approaches for endometrial cancer now and in the near future.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, and Chris Fine, MD, FACC, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

In season 3, episode 7 of Targeted Talks, John Nakayama, MD, discusses updates in the endometrial cancer treatment landscape.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

In season 2, episode 10 of Targeted Talks, Sandra P. D'Angelo, MD, and Katherine Poruk, MD, discuss frontline treatment practices in the sarcoma space.

In season 2, episode 9 of Targeted Talks, Sandy Srinivas, MD and Nicholas J. Vogelzang, MD, discuss he optimal sequencing of therapies for a specific patient with metastatic castration-resistant prostate cancer.

In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.

In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.

Jason Luke, MD, leads a discussion with Sandip Patel, MD, about the present and future of immunotherapy in cancer.